Cargando…

Need for and relevance of prostate cancer screening in Nigeria

Prostate cancer (PCa) has become the most prevalent cancer among males in Nigeria, and similar to other black populations, Nigerian men present with more advanced disease at an earlier age than in several other ethnic groups. In this unscreened, high-risk group, the reference range for early detecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinremi, TO, Adeniyi, A, Olutunde, A, Oduniyi, A, Ogo, CN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154944/
https://www.ncbi.nlm.nih.gov/pubmed/25228913
http://dx.doi.org/10.3332/ecancer.2014.457
_version_ 1782333510282903552
author Akinremi, TO
Adeniyi, A
Olutunde, A
Oduniyi, A
Ogo, CN
author_facet Akinremi, TO
Adeniyi, A
Olutunde, A
Oduniyi, A
Ogo, CN
author_sort Akinremi, TO
collection PubMed
description Prostate cancer (PCa) has become the most prevalent cancer among males in Nigeria, and similar to other black populations, Nigerian men present with more advanced disease at an earlier age than in several other ethnic groups. In this unscreened, high-risk group, the reference range for early detection and diagnosis as well as risk factors need to be determined through large-scale screening. Over 4 years, 1124 previously unscreened men between 40 and 85 years of age were screened at free community health programmes for PCa, using the common parameters of prostate-specific antigen (PSA) plus digital rectal examination (DRE). We thereby assessed the practicality and importance of screening. Consent was obtained, demographic data obtained, PSA measured using qualitative laboratory kits, and DRE performed by surgeons. We found that the number of men attending and consenting to screening increases from year to year. Of 40–85-year-old men, 85.4% consented, of whom 33.3% (a third) and 60% were 51–60 years old and 51–65 years, respectively. While 11.5% of men had PSA >4 ng/ml, 31.45% showed abnormal DRE. Of the men who took the PSA test, 79.2% also consented to the DRE, of whom 5.8% had combined abnormal DRE and PSA >4 ng/ml. Our findings suggest that Nigerian men are a willing group for screening by both the PSA and DRE with the positive response to calls for health screening and interest in prostate health. The finding of PSA >4 ng/ml in 11.15% of this population reveals the need for greater awareness and measures to increase early detection. However, the value and validity of established PSA reference ranges and cutoff of ‘normal’ still need to be established. Screening is very important to better define the PCa prevalence and characteristics in our population; otherwise political and economic circumstances will ensure that men still present late with aggressive PCa.
format Online
Article
Text
id pubmed-4154944
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-41549442014-09-16 Need for and relevance of prostate cancer screening in Nigeria Akinremi, TO Adeniyi, A Olutunde, A Oduniyi, A Ogo, CN Ecancermedicalscience Review Prostate cancer (PCa) has become the most prevalent cancer among males in Nigeria, and similar to other black populations, Nigerian men present with more advanced disease at an earlier age than in several other ethnic groups. In this unscreened, high-risk group, the reference range for early detection and diagnosis as well as risk factors need to be determined through large-scale screening. Over 4 years, 1124 previously unscreened men between 40 and 85 years of age were screened at free community health programmes for PCa, using the common parameters of prostate-specific antigen (PSA) plus digital rectal examination (DRE). We thereby assessed the practicality and importance of screening. Consent was obtained, demographic data obtained, PSA measured using qualitative laboratory kits, and DRE performed by surgeons. We found that the number of men attending and consenting to screening increases from year to year. Of 40–85-year-old men, 85.4% consented, of whom 33.3% (a third) and 60% were 51–60 years old and 51–65 years, respectively. While 11.5% of men had PSA >4 ng/ml, 31.45% showed abnormal DRE. Of the men who took the PSA test, 79.2% also consented to the DRE, of whom 5.8% had combined abnormal DRE and PSA >4 ng/ml. Our findings suggest that Nigerian men are a willing group for screening by both the PSA and DRE with the positive response to calls for health screening and interest in prostate health. The finding of PSA >4 ng/ml in 11.15% of this population reveals the need for greater awareness and measures to increase early detection. However, the value and validity of established PSA reference ranges and cutoff of ‘normal’ still need to be established. Screening is very important to better define the PCa prevalence and characteristics in our population; otherwise political and economic circumstances will ensure that men still present late with aggressive PCa. Cancer Intelligence 2014-08-28 /pmc/articles/PMC4154944/ /pubmed/25228913 http://dx.doi.org/10.3332/ecancer.2014.457 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Akinremi, TO
Adeniyi, A
Olutunde, A
Oduniyi, A
Ogo, CN
Need for and relevance of prostate cancer screening in Nigeria
title Need for and relevance of prostate cancer screening in Nigeria
title_full Need for and relevance of prostate cancer screening in Nigeria
title_fullStr Need for and relevance of prostate cancer screening in Nigeria
title_full_unstemmed Need for and relevance of prostate cancer screening in Nigeria
title_short Need for and relevance of prostate cancer screening in Nigeria
title_sort need for and relevance of prostate cancer screening in nigeria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154944/
https://www.ncbi.nlm.nih.gov/pubmed/25228913
http://dx.doi.org/10.3332/ecancer.2014.457
work_keys_str_mv AT akinremito needforandrelevanceofprostatecancerscreeninginnigeria
AT adeniyia needforandrelevanceofprostatecancerscreeninginnigeria
AT olutundea needforandrelevanceofprostatecancerscreeninginnigeria
AT oduniyia needforandrelevanceofprostatecancerscreeninginnigeria
AT ogocn needforandrelevanceofprostatecancerscreeninginnigeria